Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. - Wikidata - wikimedia - TriplyDB

Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan.

Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan.

http://www.wikidata.org/entity/Q37224099

about

Medication-related osteonecrosis of the jaw: Clinical and practical guidelines Medication Related Osteonecrosis of the Jaw: 2015 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons Human isoprenoid synthase enzymes as therapeutic targets Diagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation Oncology Efficacy and tolerability of medical ozone gas insufflations in patients with osteonecrosis of the jaw treated with bisphosphonates-Preliminary data: Medical ozone gas insufflation in treating ONJ lesions Targeted treatments of bone metastases in patients with lung cancer Implant failure associated with oral bisphosphonate-related osteonecrosis of the jaw.Bisphosphonate-associated osteonecrosis of the jaw, with healing after teriparatide: a review of the literature and a case report.Prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patients Bisphosphonates-related osteonecrosis of the jaws: a concise review of the literature and a report of a single-centre experience with 151 patients.Improving management of patients with advanced cancer Zoledronate effects on systemic and jaw osteopenias in ovariectomized periostin-deficient mice Management of bisphosphonate-related osteonecrosis of the jaw: a literature review.Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases.Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw.Osteonecrosis of the jaws in 194 patients who have undergone intravenous bisphosphonate therapy in Spain.Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases Prevention and Treatment of Bone Metastases in Breast Cancer Spontaneous osteonecrosis of the jaws in the maxilla of mice on antiresorptive treatment: a novel ONJ mouse model Evolution of bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma and Waldenstrom's macroglobulinemia: a retrospective multicentric study Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid.The effect of the duration of intravenous zolendronate medication on the success of non-surgical endodontic therapy: a retrospective study.Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art Importance of antiresorptive therapies for patients with bone metastases from solid tumors.The Prevention of Medication-related Osteonecrosis of the Jaw.Protection of bone in premenopausal women with breast cancer: focus on zoledronic acid Oral care and the use of bone-targeted agents in patients with metastatic cancers: A practical guide for dental surgeons and oncologists.Bone metastases: Are we failing our patients?Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.Randomized clinical trial of zoledronic acid in multiple myeloma patients undergoing high-dose chemotherapy and stem-cell transplantation.Periodontal disease and bisphosphonates induce osteonecrosis of the jaws in the rat.Decreasing frequency of osteonecrosis of the jaw in cancer and myeloma patients treated with bisphosphonates: the experience of the oncology network of piedmont and aosta valley (north-Western Italy)First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial New and emerging therapies for bone metastases in genitourinary cancers.International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.Periapical disease and bisphosphonates induce osteonecrosis of the jaws in mice.Pathophysiology of Osteonecrosis of the Jaws.Treatment of osteonecrosis of the jaw related to bisphosphonates and other antiresorptive agents.The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network.Osteonecrosis of the jaw and bisphosphonate use in breast cancer patients.

P2860

Q26749965-E601D50C-6FBF-4CEE-9929-EF5EDFCAF09B Q26771715-985D97DD-7054-4722-94E7-B0D05294F30F Q26822639-D4ED3EFD-696B-4EC4-AC6C-3502111CFB8C Q28076646-ADA4E47D-EAD8-4402-A99E-8B31CB05DF9A Q31048683-CF53C1E5-6A38-4818-9812-71C8B4CD4376 Q33759713-733F5559-C183-405F-B0BE-032F0F6CD898 Q33861392-3A4624FA-C2E8-4D04-8D35-0AF514BDEE0C Q33898150-98202B6B-9435-41EE-BDB8-C205ED24D0D5 Q34031441-A7919695-45A2-4D5F-8552-55A7E37F0B02 Q34035088-85816778-7FC8-4A6D-9341-A6C418B800FD Q34413634-D244455F-BF92-4696-97D7-4CEFDC742724 Q34626012-2456A376-65C5-4A00-98BC-4AC434791BBF Q35570290-E28BCB4C-C6EA-4C54-8456-51AF8297F063 Q35583788-5D0B6061-6CBE-4E49-8A00-1406CBCDF936 Q35584343-B09C42BC-9512-4899-A2FE-A2DF7B2B1117 Q35732126-11FDC9CB-E65C-4527-A474-8EE2C75986D2 Q35750641-250BA639-3061-44A0-B259-B1F5149F6B9D Q35750652-E39F2BE8-B605-4F5F-A2B6-67D98BCF5ECA Q35764778-C1D4446F-C950-484F-A646-372AB697BF35 Q35865686-F636B1D7-EA7A-4F9F-A1ED-D587808AF817 Q35865726-D10D110D-CADA-4295-8FBF-B14FDBF2DBFA Q35910376-263F34CD-8EB4-4326-B557-6FC04FFF622C Q36278556-2B309430-4230-456C-941B-F5EF0D4CDAF2 Q36283738-0ED579A7-5CA6-46F2-97D7-A20D9FE936BE Q36292333-66BFCEE6-B27B-450B-88BC-278AA472D174 Q36394320-C59ABAA2-E8B3-4865-BC5A-50A2C6AF9E9E Q36491413-EC3BDDD3-CF23-41F1-B004-0330F6268131 Q36492217-F4F06CD2-AF3B-4077-A892-58037810DB19 Q36553506-ECD7A8DD-2F57-427E-A638-D1B307FDABF4 Q36568586-9A4EF2F2-95F6-4840-B27C-3E2CFCA5A336 Q36681335-27E25D05-2C33-4539-9927-24B7D764F7CE Q36691952-B02DCE0A-AF04-4C69-9428-A90899867DC5 Q36804951-516A1A3E-EFEB-4F50-B432-0C7BA74105D9 Q36866291-1538C9AF-12F9-41F8-BFCB-059B75EF4714 Q36929923-1C9430A9-0FDD-4AB4-8477-65E496BCA9EA Q36945036-0DC8434A-AC52-4A2A-8A97-4C4498ADD163 Q37006852-2B44721A-9127-48A1-AC74-06EE585EB321 Q37217775-AB4F64D1-C9B5-4F8E-BADF-0F3D3BABC395 Q37493951-19912A14-3987-4F24-ACFF-C5B35F599EBC Q37577926-404387B5-C025-40C5-B92E-FA9BFD9FFBC4

P2860

Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan.

http://www.wikidata.org/entity/Q37224099

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 22 July 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Decreased occurrence of osteon ...... nal Cancer Institute of Milan.

@en

Decreased occurrence of osteon ...... nal Cancer Institute of Milan.

@nl

type

label

Decreased occurrence of osteon ...... nal Cancer Institute of Milan.

@en

Decreased occurrence of osteon ...... nal Cancer Institute of Milan.

@nl

prefLabel

Decreased occurrence of osteon ...... nal Cancer Institute of Milan.

@en

Decreased occurrence of osteon ...... nal Cancer Institute of Milan.

@nl

P1433

Q37224099-BFD32A1D-3B78-4B7D-BC88-D6620A06588A

P1476

Q37224099-98B8D055-8563-4DE5-87C4-83A3A8A1337B

P2093

Q37224099-04BD13DD-D2C7-497A-9EF2-069BD91D4AD6

Q37224099-37ED56CB-C15B-4718-B887-82BCFAB54570

Q37224099-6B1B1DDB-CF58-482D-A575-68A26C975596

Q37224099-B7D4D379-2D07-4010-B070-80AB43A2EE6D

Q37224099-D93F9296-D881-4BFD-BABC-24915D947FB2

Q37224099-E072F483-7370-4E4E-9127-2415DBE81ABC

Q37224099-E0A50E7C-C4A8-4B6C-B328-1F65192634BD

P2860

Q37224099-0E498ACF-E9BA-4AED-9132-62363BC2BA0D

Q37224099-11C4BF8D-F16C-4DE4-8A65-9E54AACCCD84

Q37224099-128E7A22-AA85-4EC7-9BB3-70B9D5A234E4

Q37224099-169DAEC5-F05E-4D3B-A070-7B66FB7D28BC

Q37224099-20B1A398-7182-48DC-9A15-395D2CAC69C5

Q37224099-311BE750-5BBA-4900-A9AD-A6E27087DDEA

Q37224099-313A4D50-4F90-4FA6-B7E4-E37155A023B9

Q37224099-397BADE0-12A1-4E60-B112-E382C986A76E

Q37224099-3B27FAF5-F2DA-41DE-8A70-E82A7F5268B4

Q37224099-4603BCAB-B700-4D07-8B21-52E381F18AB5

P304

Q37224099-65D3DCD1-237A-4D32-B5EB-241F8ED501B5

P31

Q37224099-9C07A4B8-B981-4DEA-82B8-1EF3098F84AB

P356

Q37224099-CD00C63D-565E-4896-A1EB-3C2C0BD3F6D9

P433

Q37224099-FE903245-EAD2-45FD-B18C-7DEEFFF9F486

P478

Q37224099-D3441504-DC43-4CBD-BCB6-F82BE6BF7033

P50

Q37224099-6FA1DD58-23A9-4106-8427-CF591E1FE4AB

Q37224099-FE3D023A-AD63-43D9-BF29-BFE903A89B67

P577

Q37224099-E8930150-CBA2-48E2-A517-3A82576DB070

P698

Q37224099-CEBDC04D-55BD-4C39-BF1C-5D26F9343A6F

P921

Q37224099-2BD015D6-8B6B-4F00-A11B-E2D035549AE9

P356

P1433

Annals of Oncology

P1476

Decreased occurrence of osteon ...... onal Cancer Institute of Milan

@en

P2093

C Bareggi

http://www.w3.org/2001/XMLSchema#string

E Cislaghi

http://www.w3.org/2001/XMLSchema#string

E Fagnoni

http://www.w3.org/2001/XMLSchema#string

G Saibene

http://www.w3.org/2001/XMLSchema#string

L Ascani

http://www.w3.org/2001/XMLSchema#string

M Maniezzo

http://www.w3.org/2001/XMLSchema#string

T Campa

http://www.w3.org/2001/XMLSchema#string

P2860

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws

Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment

American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma.

American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel.

Mechanisms of bone metastasis.

American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.

Bisphosphonate therapy in multiple myeloma: past, present, future.

Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens

Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy.

P304

137-145

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDN526

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Carla Ripamonti

P577

2008-07-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18647964

http://www.w3.org/2001/XMLSchema#string

P921